Mavik (trandolapril)

Knoll Pharmaceutical

Approval Status
Approved May 1996

Treatment for

Cardiovascular / Cardiology , Diabetes / Endocrinology

Mavik is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension when used alone or in combination with other antihypertensive medication, such as hydrochlorothiazide. Knoll Pharmaceutical Company expects to make Mavik available by prescription in one mg, two mg, and four mg dosage strengths. In Afro-American subjects, the minimal effective daily dose is two mg (versus one mg in Caucasians).

In clinical studies, Mavik was shown to provide excellent 24-hour blood pressure control when taken once daily.

Mavik was well tolerated in clinical trials. The most common side effects were cough (1.9%), dizziness (1.3%), and diarrhea (1.0%). Headache and fatigue occurred in less than 1% of patients, but were reported more often on placebo. Mavik is contraindicated in subjects who are hypersensitive to the product. Angiodema has been reported in subjects receiving ACE inhibitors.

The clinical significance of tissue ACE inhibition has not been established.

Mavik (trandolapril) Drug Information

The Mavik (trandolapril) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top